Arcutis Net Income From Continuing Ops vs Ebit Analysis

ARQT Stock

USD 10.77 0.63 6.21%

Arcutis Biotherapeutics financial indicator trend analysis is way more than just evaluating Arcutis Biotherapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Arcutis Biotherapeutics is a good investment. Please check the relationship between Arcutis Biotherapeutics Net Income From Continuing Ops and its Ebit accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arcutis Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index.

For more information on how to buy Arcutis Stock please use our How to Invest in Arcutis Biotherapeutics guide.

Net Income From Continuing Ops vs Ebit

Net Income From Continuing Ops vs Ebit Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Arcutis Biotherapeutics Net Income From Continuing Ops account and Ebit. At this time, the significance of the direction appears to have totally related.

The correlation between Arcutis Biotherapeutics' Net Income From Continuing Ops and Ebit is 1.0. Overlapping area represents the amount of variation of Net Income From Continuing Ops that can explain the historical movement of Ebit in the same time period over historical financial statements of Arcutis Biotherapeutics, assuming nothing else is changed. The correlation between historical values of Arcutis Biotherapeutics' Net Income From Continuing Ops and Ebit is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income From Continuing Ops of Arcutis Biotherapeutics are associated (or correlated) with its Ebit. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebit has no effect on the direction of Net Income From Continuing Ops i.e., Arcutis Biotherapeutics' Net Income From Continuing Ops and Ebit go up and down completely randomly.

Correlation Coefficient

1.0

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Net Income From Continuing Ops

Ebit

Most indicators from Arcutis Biotherapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Arcutis Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arcutis Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index.

For more information on how to buy Arcutis Stock please use our How to Invest in Arcutis Biotherapeutics guide.At this time, Arcutis Biotherapeutics' Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to about 3.3 M in 2024, despite the fact that Enterprise Value Multiple is likely to grow to (1.43).

Arcutis Biotherapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Long Term Debt	Cash And Short Term Investments	Common Stock Shares Outstanding	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Other Liab	Non Current Liabilities Other	Short Long Term Debt Total	Property Plant And Equipment Net	Other Assets
Total Assets		0.96	0.96	0.87	0.92	0.53	-0.82	0.94	0.88	0.86	1.0	0.91	0.82	0.71	0.93	0.87	0.88	0.78	0.97	1.0	1.0	-0.93	0.67	0.82	0.95	0.94
Other Current Liab	0.96		1.0	0.78	0.9	0.64	-0.89	0.99	0.86	0.9	0.94	0.97	0.77	0.75	0.95	0.91	0.92	0.82	0.94	0.96	0.95	-0.95	0.56	0.91	0.9	0.97
Total Current Liabilities	0.96	1.0		0.78	0.9	0.64	-0.9	0.99	0.86	0.9	0.93	0.96	0.78	0.75	0.95	0.91	0.93	0.82	0.94	0.95	0.94	-0.95	0.55	0.91	0.9	0.97
Total Stockholder Equity	0.87	0.78	0.78		0.95	0.28	-0.57	0.77	0.7	0.54	0.9	0.64	0.59	0.28	0.8	0.68	0.74	0.38	0.93	0.88	0.88	-0.84	0.88	0.54	0.95	0.84
Net Tangible Assets	0.92	0.9	0.9	0.95		0.4	-0.71	0.9	0.78	0.67	0.91	0.79	0.65	0.41	0.88	0.79	0.83	0.52	0.96	0.92	0.91	-0.91	0.83	0.68	0.97	0.94
Net Debt	0.53	0.64	0.64	0.28	0.4		-0.84	0.61	0.28	0.71	0.49	0.62	0.33	0.61	0.69	0.65	0.78	0.64	0.57	0.52	0.51	-0.7	-0.16	0.87	0.45	0.6
Retained Earnings	-0.82	-0.89	-0.9	-0.57	-0.71	-0.84		-0.89	-0.74	-0.9	-0.78	-0.9	-0.74	-0.78	-0.94	-0.95	-0.97	-0.83	-0.79	-0.82	-0.8	0.92	-0.27	-0.93	-0.77	-0.9
Accounts Payable	0.94	0.99	0.99	0.77	0.9	0.61	-0.89		0.86	0.91	0.91	0.95	0.8	0.72	0.94	0.9	0.92	0.8	0.92	0.94	0.93	-0.93	0.57	0.88	0.9	0.98
Cash	0.88	0.86	0.86	0.7	0.78	0.28	-0.74	0.86		0.8	0.88	0.89	0.94	0.74	0.83	0.87	0.75	0.79	0.76	0.88	0.88	-0.79	0.66	0.65	0.83	0.85
Long Term Debt	0.86	0.9	0.9	0.54	0.67	0.71	-0.9	0.91	0.8		0.83	0.92	0.86	0.91	0.85	0.84	0.86	0.95	0.78	0.86	0.85	-0.83	0.27	0.92	0.74	0.85
Cash And Short Term Investments	1.0	0.94	0.93	0.9	0.91	0.49	-0.78	0.91	0.88	0.83		0.89	0.82	0.68	0.91	0.85	0.86	0.75	0.96	1.0	1.0	-0.92	0.7	0.78	0.95	0.92
Common Stock Shares Outstanding	0.91	0.97	0.96	0.64	0.79	0.62	-0.9	0.95	0.89	0.92	0.89		0.81	0.86	0.9	0.92	0.87	0.91	0.84	0.91	0.9	-0.88	0.44	0.9	0.81	0.91
Long Term Debt Total	0.82	0.77	0.78	0.59	0.65	0.33	-0.74	0.8	0.94	0.86	0.82	0.81		0.78	0.78	0.81	0.72	0.81	0.67	0.82	0.82	-0.73	0.5	0.63	0.76	0.77
Non Current Liabilities Total	0.71	0.75	0.75	0.28	0.41	0.61	-0.78	0.72	0.74	0.91	0.68	0.86	0.78		0.66	0.72	0.66	0.99	0.56	0.7	0.7	-0.62	0.04	0.83	0.49	0.63
Capital Surpluse	0.93	0.95	0.95	0.8	0.88	0.69	-0.94	0.94	0.83	0.85	0.91	0.9	0.78	0.66		0.97	0.99	0.74	0.92	0.93	0.92	-0.99	0.56	0.86	0.93	0.97
Other Current Assets	0.87	0.91	0.91	0.68	0.79	0.65	-0.95	0.9	0.87	0.84	0.85	0.92	0.81	0.72	0.97		0.95	0.78	0.82	0.87	0.86	-0.94	0.48	0.83	0.86	0.93
Other Stockholder Equity	0.88	0.92	0.93	0.74	0.83	0.78	-0.97	0.92	0.75	0.86	0.86	0.87	0.72	0.66	0.99	0.95		0.73	0.89	0.88	0.87	-0.98	0.45	0.89	0.88	0.95
Total Liab	0.78	0.82	0.82	0.38	0.52	0.64	-0.83	0.8	0.79	0.95	0.75	0.91	0.81	0.99	0.74	0.78	0.73		0.65	0.78	0.77	-0.7	0.13	0.88	0.59	0.72
Net Invested Capital	0.97	0.94	0.94	0.93	0.96	0.57	-0.79	0.92	0.76	0.78	0.96	0.84	0.67	0.56	0.92	0.82	0.89	0.65		0.97	0.96	-0.95	0.69	0.81	0.96	0.94
Total Current Assets	1.0	0.96	0.95	0.88	0.92	0.52	-0.82	0.94	0.88	0.86	1.0	0.91	0.82	0.7	0.93	0.87	0.88	0.78	0.97		1.0	-0.93	0.67	0.82	0.95	0.94
Net Working Capital	1.0	0.95	0.94	0.88	0.91	0.51	-0.8	0.93	0.88	0.85	1.0	0.9	0.82	0.7	0.92	0.86	0.87	0.77	0.96	1.0		-0.92	0.68	0.8	0.95	0.93
Other Liab	-0.93	-0.95	-0.95	-0.84	-0.91	-0.7	0.92	-0.93	-0.79	-0.83	-0.92	-0.88	-0.73	-0.62	-0.99	-0.94	-0.98	-0.7	-0.95	-0.93	-0.92		-0.57	-0.86	-0.94	-0.97
Non Current Liabilities Other	0.67	0.56	0.55	0.88	0.83	-0.16	-0.27	0.57	0.66	0.27	0.7	0.44	0.5	0.04	0.56	0.48	0.45	0.13	0.69	0.67	0.68	-0.57		0.18	0.8	0.64
Short Long Term Debt Total	0.82	0.91	0.91	0.54	0.68	0.87	-0.93	0.88	0.65	0.92	0.78	0.9	0.63	0.83	0.86	0.83	0.89	0.88	0.81	0.82	0.8	-0.86	0.18		0.7	0.83
Property Plant And Equipment Net	0.95	0.9	0.9	0.95	0.97	0.45	-0.77	0.9	0.83	0.74	0.95	0.81	0.76	0.49	0.93	0.86	0.88	0.59	0.96	0.95	0.95	-0.94	0.8	0.7		0.95
Other Assets	0.94	0.97	0.97	0.84	0.94	0.6	-0.9	0.98	0.85	0.85	0.92	0.91	0.77	0.63	0.97	0.93	0.95	0.72	0.94	0.94	0.93	-0.97	0.64	0.83	0.95

Click cells to compare fundamentals

Arcutis Biotherapeutics Account Relationship Matchups

Arcutis Biotherapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	107.0M	298.3M	408.2M	449.3M	341.4M	260.7M
Other Current Liab	3.7M	15.5M	25.1M	27.7M	33.2M	16.7M
Total Current Liabilities	5.2M	22.6M	33.3M	37.8M	46.7M	23.4M
Total Stockholder Equity	(65.0M)	270.6M	297.7M	209.6M	88.7M	121.4M
Net Tangible Assets	(65.0M)	270.6M	297.7M	202.4M	232.8M	124.1M
Net Debt	(63.0M)	(60.1M)	(18.9M)	148.9M	117.5M	123.4M
Retained Earnings	(66.3M)	(202.0M)	(408.3M)	(719.8M)	(981.9M)	(932.8M)
Accounts Payable	1.4M	7.1M	7.4M	8.8M	12.0M	6.1M
Cash	63.3M	65.1M	96.4M	53.6M	88.4M	64.4M
Non Current Assets Total	538K	5.4M	5.4M	11.9M	10.9M	11.5M
Cash And Short Term Investments	101.3M	284.4M	387.1M	409.6M	271.9M	237.1M
Common Stock Shares Outstanding	38.1M	35.7M	49.4M	55.0M	69.3M	44.6M
Short Term Investments	37.9M	219.4M	290.6M	355.9M	183.5M	172.7M
Liabilities And Stockholders Equity	107.0M	298.3M	408.2M	449.3M	341.4M	260.7M
Non Current Liabilities Total	166.8M	5.0M	77.1M	201.9M	206.0M	115.9M
Capital Surpluse	289K	1.2M	472.6M	706.2M	812.2M	852.8M
Other Current Assets	5.2M	7.9M	15.7M	11.8M	19.6M	20.6M
Other Stockholder Equity	(165.2M)	472.6M	706.2M	930.4M	1.1B	1.1B
Total Liab	172.0M	27.6M	110.5M	239.7M	252.7M	139.3M
Net Invested Capital	(65.0M)	270.6M	370.0M	407.4M	290.5M	195.6M
Total Current Assets	106.5M	292.8M	402.8M	437.4M	330.4M	255.3M
Net Working Capital	101.2M	270.2M	369.4M	399.6M	283.8M	231.9M
Non Current Liabilities Other	184K	5.0M	4.8M	849K	976.4K	927.5K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Arcutis Stock Analysis

When running Arcutis Biotherapeutics' price analysis, check to measure Arcutis Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcutis Biotherapeutics is operating at the current time. Most of Arcutis Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Arcutis Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcutis Biotherapeutics' price. Additionally, you may evaluate how the addition of Arcutis Biotherapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC